Andere Sprachen Centessa Pharmaceuticals plc

Aktien

A3CQ72

US1523091007

CNTA

Realtime-Estimate Cboe BZX Andere Börsenplätze 17:10:37 03.05.2024			% 5 Tage	% 1. Jan.
9,505 ^USD	-0,47 %		+7,06 %	+19,97 %

24.04.	Börsengehandelte Fonds höher, Aktienfutures vor dem Glockenschlag am Mittwoch uneinheitlich inmitten der Gewinnflut	MT
24.04.	Centessa Pharmaceuticals bepreist Aktienangebot mit $9,25 pro ADS	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Wednesday Amid Earnings Deluge	24.04.
Centessa Pharmaceuticals Prices Equity Offering at $9.25 Per ADS	24.04.
Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares	24.04.
Centessa Pharmaceuticals Eyes $100 Million in ADS Offering	24.04.
Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares	23.04.
Centessa Pharmaceuticals Announces Open IND for ORX750, Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024	23.04.
Centessa Pharmaceutical Gets FDA's Approval to Begin Phase 1 Trial of Narcolepsy Drug Candidate	22.04.
Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024	22.04.
Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024	22.04.
Centessa Pharmaceuticals plc Announces Open IND for ORX750	22.04.
Centessa Pharmaceuticals plc Reports Earnings Results for the Full Year Ended December 31, 2023	28.03.
Centessa Pharmaceuticals plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28.03.
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023	28.03.
Centessa Pharmaceuticals Insider Sold Shares Worth $607,960, According to a Recent SEC Filing	26.03.
Centessa Pharmaceuticals : March Corporate Overview	05.03.
Centessa Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference	22.02.
Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)	09.02.
Scion Life Sciences Launches with Oversubscribed $310 Million Fund to Create and Build Exceptional Biotech Companies	08.02.
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences	22.01.
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences	22.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Centessa Pharmaceuticals plc

Aktien

A3CQ72

US1523091007

CNTA

Andere Sprachen

Filter